Objective: To study drug consumption with indication in osteoporosis and those drugs which complement them. Design: Longitudinal descriptive. Placement: Annual prescription by recipe from the Social Security in Catalonia (6 million inhabitants) from 1992 to 1999. Measurements and Principal Results: In 1999, the consumption was 2.4 million containers for a value of 5,911 million pesetas, with increases with respect to 1992 of a 78% and a 77% respectively. The average cost per container remained constant. The use of estrogens and others related, mostly estradiol in patches, was of 6,552 DDD/1,000,000 inhabitants/day (D1MHD) with an increase of a 427% with respect to 1992, the use of diphosphonates, mainly allendronate, was of 2,139 D1MHD (plus 1,481%), the use of calcitonins, above all of nasal salmon, was of 1,425 D1MHD (plus 55%) and the use of raloxiphene was of 570 D1MHD. It grew consumption of specialties with simultaneous estrogenic and progestogenic activity reching 40% of the D1MHD of estrogens. The consumption of progestogens increased four times and reached 2, 622 D1MHD. The use of vitamin D was of 1,028 D1MHD. Although the use of calcium supplements stabilized around the million containers, their cost per container tripled. Conclusions: The group of drugs being studied experienced a strong increase in their consumption, the estrogens and, from a distance, the diphosphonates were the most used and the highest growing groups. It grew the consumption of specialties with simultaneous estrogenic and progestogenic activity. After years of stable consumption, the calcitonin finally grew. The raloxiphene is envisaged as one more alternative. The use of calcium supplements stabilized itself
© 2001-2024 Fundación Dialnet · Todos los derechos reservados